In a 6,016-person heart attack trial, a modest absolute benefit proves substantial

Cardiology advances are often reported as hazard ratios. For the person arriving with a major heart attack, the more useful question is what happens in the year after the artery is opened. The BRIGHT-4 trial followed more than six thousand patients undergoing primary coronary intervention, and compared two anticoagulation strategies under a precisely defined procedural protocol.

The comparison matters: bivalirudin here was not simply given instead of heparin. It was followed by a high-dose infusion for two to four hours, and the patients largely underwent radial-access PCI. Those details constrain where the result applies. The composite reduction was supported by less major bleeding and stent thrombosis; death by itself was not conclusively lower.

For clinical practice this is a specialist protocol decision, requiring review of contemporary guideline recommendations, patient bleeding risk, cost and catheterization-lab workflow. It is not an invitation to generalize anticoagulation choices outside the trial setting.

The evidence: Open-label, multicenter RCT; 6,016 people with STEMI receiving radial-access primary PCI; 3,009 assigned bivalirudin plus full-dose post-PCI infusion and 3,007 heparin alone. At 12 months, death or BARC grade 3–5 bleeding occurred in 4.1% versus 5.6% (HR 0.73; 95% CI 0.58–0.92): an absolute 1.5-percentage-point difference, roughly 15 fewer events per 1,000 treated. Major bleeding was 0.6% versus 1.2%; stent thrombosis 0.8% versus 1.3%. The all-cause mortality difference alone (3.8% versus 4.8%) was not statistically significant (P=0.08).

unsupervised treatment change.